The Medical Sisterhood: Physician Mom Burnout & Mental Health Strategies, with Jennifer Hsiao, MD

, host Mona Shahriari, MD, associate clinical professor of dermatology at Yale School of Medicine, welcomes Jennifer Hsiao, MD, a dermatologist and clinical associate professor of clinical dermatology at Keck Medicine of the University of Southern California (USC), for a thoughtful discussion on leadership, visibility, and building a meaningful academic career in dermatology.

The pair discuss the invisible labor of love faced by female physicians, particularly mothers. They explore the mental checklists, calendar management, and the constant juggling of professional and personal responsibilities. Hsiao shares her experience as a dermatologist and mother of two, highlighting the challenges of maintaining work-life balance and the societal expectations placed on mothers. They emphasize the importance of community support, setting boundaries, and the need for shared responsibilities at home.

The conversation centers on the evolving role of women in academic medicine and the unique pressures that come with balancing clinical excellence, scholarship, and personal fulfillment. Hsiao reflects on her path into dermatology and academia, emphasizing that career trajectories are rarely linear. Rather than following a rigid roadmap, she describes making intentional decisions rooted in mentorship, curiosity, and alignment with her long-term values.

A key theme throughout the episode is the importance of visibility—particularly for women physicians navigating leadership spaces. Another focal point of the discussion is redefining success. Hsiao challenges the notion that academic achievement must come at the expense of personal well-being. Instead, she encourages physicians to regularly reassess their goals and ensure that their work aligns with what brings them fulfillment, whether that be research, teaching, clinical care, or leadership.

Throughout the episode, Shahriari and Hsiao acknowledge that while structural barriers still exist, there is increasing space for women to lead authentically and collaboratively. They emphasized the importance of advocating for themselves in modern society. The conversation concludes with reflections on the evolving roles of women in medicine and the need for grace and self-compassion.

Editor’s note: This summary was edited with the help of AI tools.

Videos

The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Image Credit: US Food and Drug Administration

Announced by parent company Eton Pharmaceuticals on February X, 2026, the 

 has approved ET-600 to treat central diabetes insipidus among pediatric patients.

ET-600, now under the label Desmoda, is the first and only FDA-approved oral liquid formulation of desmopressin. It will be supplied as a ready-to-use oral solution of 0.05 mg/mL that does not require tablet splitting, crushing, refrigeration, mixing, or shaking.

“In central diabetes insipidus, effective long-term management depends on accurately matching desmopressin dosing to each patient’s diurnal pattern of water balance,” Sean Brynjelsen, chief executive officer of Eton Pharmaceuticals, said in a statement. “Historically, clinicians have primarily relied on formulations that were not designed for fine dose adjustments or had other administration issues, and both clinicians and families often had to rely on workarounds. Desmoda introduces a liquid solution designed to deliver individualized dosing precision and consistency for patients across the age spectrum.”

 is a rare, complex disease wherein large volumes of dilute urine are excreted due to arginine-vasopressin deficiency (AVP-D). Its causes can be genetic, congenital, inflammatory, neoplastic, and traumatic, but mainly involve conditions arising from the hypothalamus.

Early diagnosis and treatment are crucial for pediatric patients in particular, given the disease’s potential for central nervous system damage and the risk of dissemination of germ cell tumor. Additionally, the disease can progress into Langerhans Cell Histiocytosis and additional pituitary defects.

Among the challenges presented by the disease is the differential diagnosis between central diabetes insipidus presenting with polyuria and polydipsia. This process requires a detailed medical history, biochemical approach, physical examination, imaging studies, and potentially histological confirmation. Pituitary stalk size is variable and can change depending on the underlying condition, and other brain areas or organs can become involved during follow-up.

Desmopressin is a synthetic vasopressin analog first approved in 1978 to manage diabetes insipidus, as well as hemophilia A and von Willebrand’s disease. ET-600 is the first oral liquid formulation of desmopressin. Eton Pharmaceuticals has received a patent for the formulation extending to 2044, with an additional patent under review.

The FDA’s decision was based on results from a bioequivalence study completed in March of 2025. Investigators from Eton enrolled 75 patients, who were then randomly assigned to receive the test and reference drug in an open-label, balanced, randomized, single-dose, 3-treatment, 3-sequence, 3-period, 3-way crossover oral bioequivalence study.

Ultimately, ET-600 displayed full pharmacokinetic equivalence to the FDA-approved reference product of the same active ingredient. Following this, Eton submitted its first New Drug Application (NDA) for ET-600 to the FDA on July 8, 2025.

“Central diabetes insipidus requires careful, individualized management, where dosing precision and flexibility truly matter. Having a liquid formulation of desmopressin has the potential to meaningfully support how we initiate and manage therapy,” Lewis Blevins, director of the California Center for Pituitary Disorders and professor of medicine and neurological surgery at the University of California, San Francisco, said in a statement. “It’s encouraging to see innovation that directly addresses real-world challenges faced by clinicians and families and gives greater confidence when tailoring treatment across age groups.”

Eton Pharmaceuticals. Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA (desmopressin acetate) Oral Solution. February 25, 2026. Accessed February 25, 2026. 

https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-us-fda-approval-desmodatm

Patti G, Ibba A, Morana G, et al. Central diabetes insipidus in children: Diagnosis and management. 

Eton Pharmaceuticals. Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution). July 8, 2025. Accessed February 24, 2026. 

https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-fda-acceptance-new-drug-1

Eton Pharmaceuticals. Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600. March 14, 2025. Accessed February 24, 2026. 

https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-positive-pivotal-clinical-study

Articles

Eton Pharmaceuticals’ ET-600 (Desmoda) received FDA approval for pediatric central diabetes insipidus as the first oral liquid desmopressin formulation. The ready-to-use 0.05 mg/mL solution is designed to avoid tablet manipulation and other administration barriers, supporting finer dose titration aligned with diurnal water-balance needs. Central diabetes insipidus reflects arginine-vasopressin deficiency with heterogeneous etiologies and clinically demanding diagnostic workups, especially in children given CNS and multisystem risks. Approval was supported by a 75-subject crossover bioequivalence study demonstrating pharmacokinetic equivalence to the reference product.

The FDA has approved proprietary desmopressin oral solution formulation ET-600 for the treatment of central diabetes insipidus in children.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

FDA News

FDA Approves ET-600 Desmopressin Acetate (Desmoda) for Central Diabetes Insipidus

Mary K Roberts, PhD is a Post Doctoral Researcher at the Leverhulme Centre for Demographic Science at the University of Oxford.

Living Donor Donation Works When Relationships Matter

Despite the benefits of living donor kidney transplantation, donation rates remain low, and recent data suggests willingness to donate is shaped by more than financial concerns.

New research shows that interpersonal and health-related factors, as well as age, sex, and racial or ethnic background, strongly influence whether potential donors take steps toward donation.

“Ultimately, combining structural support with relationally grounded, culturally responsive counseling is likely more effective for increasing living donation than focusing on finances alone,” said Mary K. Roberts, PhD, postdoctoral researcher at the Leverhulme Centre for Demographic Science at the University of Oxford.

Analyzing data from 600 U.S. relatives of kidney disease patients in the 2019 

, Roberts and colleagues identified the strongest motivators and deterrents influencing donation behavior. Improving or extending the recipient’s life and the donor–recipient relationship emerged as the most important motivators, while concerns about donor health, surgery, and finances were the primary barriers.

Willingness to donate also varied across demographic groups. Younger adults were more influenced by match likelihood, current health, and knowledge of living donation, while older adults were more likely to cite their own health as a limiting factor. Women reported greater concerns about finances and recovery than men, and Black and Asian/Pacific Islander respondents were more likely to indicate that surgery or financial concerns reduced willingness. Hispanic and White respondents more often highlighted the potential to extend the recipient’s life as a motivator.

Investigators saw greater willingness was driven by health, relationship, match likelihood, and potential benefit to the recipient, and was linked to completing more donation-related actions, even after adjusting for demographic factors. Conversely, lower willingness related to general views on organ donation, surgery, or recovery predicted fewer actions, underscoring the influence of both personal and relational factors on behavior.

“Programs integrating culturally tailored, patient-focused, and family-centered education can help patients navigate these conversations with potential donors,” Roberts said. “Ensuring donors have ways to access donation services, proactively discussing medical and process concerns, and providing transparency around long-term health risks are especially critical for communities that historically experience disparities in transplant access.”

Roberts suggests improving living kidney donation rates requires a multidimensional approach that addresses both structural barriers and interpersonal concerns, rather than focusing solely on financial support. By combining culturally responsive counseling with practical and medical support, clinicians can help reduce disparities and increase donor engagement across diverse populations.

Editor’s Note: Roberts reports no relevant disclosures.

Roberts MK, Ryan-Claytor C, Salim Z, Kirk JM, Rowe-Nicholls I, Daw J. Factors influencing willingness to pursue living kidney donation among relatives of patients with kidney disease in the United States. 

. Published online February 9, 2026. doi:

https://doi.org/10.1186/s12882-026-04806-3

.DePasquale N, Cabacungan A, Ephraim PL, Lewis-Boyér L, Powe NR, Boulware LE. Family Members’ Experiences With Dialysis and Kidney Transplantation. 

https://doi.org/10.1016/j.xkme.2019.06.001

Willingness to pursue living kidney donation is shaped by relationships, health, and a multidisciplinary approach, not just finances.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Living Donor Donation Works When Relationships Matter With Mary Roberts, PhD

Mark Creager, MD, is the director emeritus of the Heart and Vascular Center at Dartmouth University.

New Pulmonary Embolism Guidelines Highlight Progress, Encourage Research, With Mark Creager, MD

On February 19, 2026, the American College of Cardiology (ACC) and American Heart Association (AHA) released a clinical practice guideline for 

 treatment, the first of its kind from these institutions.

Prominent among this guideline is a new clinical classification scheme, dividing patients into 5 main categories A through E, equivalent to low to high risk of adverse outcomes. Category A includes patients exhibiting incidental and asymptomatic embolism, with no subgroups. Category B includes symptomatic patients with a low clinical severity score and is divided into B1, including subsegmental presentation, and B2, which includes non-subsegmental.

Category C includes patients with an elevated clinical severity score and consists of 3 subgroups. C1 includes those with normal RV and normal biomarkers; C2 includes abnormal RV or ≥1 abnormal biomarker; C3 includes patients with both abnormal RV and ≥1 abnormal biomarker. Category D includes patients with incipient cardiopulmonary failure: D1 includes patients with transient hypotension, while D2 includes those with normotensive shock. Finally, Category E is cardiopulmonary failure, with E1 including recurrent or persistent hypotension with cardiogenic shock and E2 including refractory cardiogenic shock or cardiac arrest.

“This is a new clinical categorization of acute pulmonary embolism, and we’re using this to help guide clinicians who are managing patients with acute pulmonary embolism in how they can manage these patients most effectively and most safely,” Mark Creager, MD, director emeritus of the Heart and Vascular Center at Dartmouth University and chair of the guideline writing committee, told 

 in an exclusive interview. “Let me just remind everyone that this is not the first time clinical categorization has been proposed for managing acute pulmonary embolism, but this is a refinement of what we’ve seen previously based on where we are in terms of assessing pulmonary embolism and the options we have for therapeutic strategies.”

The guideline also encourages the use of direct oral anticoagulant medications over vitamin K antagonists in eligible patients, highlighting their superior efficacy in preventing recurrent venous thromboembolism and reducing major bleeding. The committee provided treatment suggestions for scenarios in which direct oral anticoagulants have not been explicitly tested, including excess body weight or hepatic disease, highlighting low-molecular-weight heparin as an efficacious alternative.

Additionally, the committee acknowledges and highlights several areas in which further research is necessary. A section towards the end of the guideline explicitly notes the need to redefine risk stratification tools, including the validation of the AHA/ACC clinical categories and using novel predictors like RV enlargement metrics and thrombus burden. Moreover, the guideline encourages research into the long-term outcomes of PE, particularly in chronic thromboembolic disease and various patient subgroups.

Although the guideline is almost all-encompassing, Creager highlighted a handful of missed opportunities, primarily patient awareness. PE is still a largely underrepresented condition, and a large swath of patients are unaware that their symptoms may fit this disease.

“What’s not covered in the guidelines, but which we need to cover, is increasing awareness of pulmonary embolism, particularly among the public,” Creager said. “People who are not aware that the symptoms they have may be a pulmonary embolism, they’re not going to do anything about it. When people get these symptoms, they have to seek care and seek it urgently, so that the diagnosis can be made promptly and appropriate treatments can be undertaken properly.”

Editor’s Note: Creager reports no relevant disclosures.

American Heart Association. First AHA/ACC acute pulmonary embolism guideline: prompt diagnosis and treatment are key. Eurekalert. February 19, 2026. Accessed February 20, 2026. 

https://www.eurekalert.org/news-releases/1116906

Creager MA, Barnes GD, Giri J, et al. 2026 AHA/ACC/ACCP/ACEP/chest/SCAI/SHM/SIR/SVM/SVN guideline for the evaluation and management of Acute Pulmonary embolism in adults: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Published online February 19, 2026. 

Creager discusses the accomplishments of the ACC and AHA’s joint PE clinical practice guideline while continuing to look to the future of the disease.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Strategic Alliance Partnership

Andres Hurtado-Lorenzo, PhD, is VP of IBD Ventures and Translational Research at the Crohn’s & Colitis Foundation.

Intermittent Fasting as Adjunct Therapy in Crohn’s Disease

As interest grows in lifestyle-based strategies to complement pharmacologic therapy in Crohn’s disease, attention is increasingly turning to interventions that target metabolism and the gut microbiome without requiring restrictive diet overhauls.

Among these, time-restricted feeding has emerged as a promising approach. Rather than changing what patients eat, this strategy restructures when they eat, leveraging circadian biology, metabolic remodeling, and immune regulation. In a recent randomized clinical trial published in 

, researchers evaluated time-restricted feeding as a complementary strategy in adults with Crohn’s in clinical remission and overweight or obesity, with findings suggesting its impact on clinical disease activity, body composition, and systemic inflammation.

, Andres Hurtado-Lorenzo, PhD, VP of IBD Ventures and Translational Research at the Crohn’s & Colitis Foundation, examined the clinical significance of recent randomized trial data and what these findings could mean for sustaining remission in Crohn’s disease.

Check out part 1 of the interview with Hurtado-Lorenzo 

In the trial, over a 12-week period, participants following a 16:8 fasting protocol experienced significant reductions in body weight and visceral fat despite consuming similar calories and foods as the control group. Hurtado-Lorenzo emphasized the importance of this observation: metabolic benefits emerged without dietary modification, underscoring meal timing as an independent variable in disease management.

Symptom improvement represented another key outcome, carrying practical significance in a condition where symptom burden often affects quality of life and treatment satisfaction. Hurtado-Lorenzo framed the findings as evidence that time-based interventions might complement existing therapies by addressing metabolic and inflammatory pathways not fully targeted by pharmacologic agents.

“These findings suggest that by targeting visceral fat, intermittent fasting can break the cycle of inflammation and metabolic dysfunction, making it a promising management strategy for conditions like Crohn's disease and overall metabolic health,” he explained.

The study also explored microbiome dynamics, revealing increases in microbial diversity and enrichment of short-chain fatty acid–producing bacteria among participants practicing intermittent fasting. Hurtado-Lorenzo highlighted this point as particularly relevant to Crohn’s disease, given the role of gut microbiota in immune regulation and intestinal inflammation.

Importantly, the discussion maintained that time-restricted feeding should not be viewed as a replacement for standard medical therapy. Instead, it represents a potential adjunct strategy, low cost and accessible, that could work in synergy with established treatments to help sustain remission.

While he says further research is required to confirm long-term benefits, the results provide early evidence that structured fasting protocols could become part of a broader, multimodal approach to inflammatory bowel disease management.

Crohn’s & Colitis Foundation of America. Intermittent fasting cut Crohn’s disease activity by 40% and halved inflammation in randomized clinical trial. February 9, 2026. Accessed February 19, 2026. 

https://www.eurekalert.org/news-releases/1114988

Haskey N, Ye J, Lewis A, Yousuf M, Reimer RA, Raman M. Time-Restricted Feeding Reduces Body Mass Index, Visceral Adiposity, Systemic Inflammation, and Clinical Disease Activity in Adults With Crohn's Disease: A Randomized Controlled Study. 

. Published online February 9, 2026. doi:10.1053/j.gastro.2025.11.008

Hurtado-Lorenzo discusses trial data showing time-restricted feeding in Crohn’s disease results in weight loss, symptom improvement, and microbiome changes.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

New Evidence on Meal Timing and Crohn’s Disease Outcomes, With Andres Hurtado-Lorenzo, PhD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Vanda Pharmaceuticals announced the FDA's acceptance of imsidolimab's Biologics License Application for the treatment of GPP.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

FDA Accepts BLA for Imsidolimab as Generalized Pustular Psoriasis Treatment

Matthew Jolley, MD, is the Topolewski Endowed Chair in Pediatric Cardiology at Children’s Hospital of Philadelphia.

Jolley discusses the team’s combination of volume rendering and cardiac MRI-based valve evaluation to provide 4D models of the heart and blood flow.

New Cardiac Imaging Method Directly Visualizes Pediatric Heart Defects, With Matthew Jolley, MD

Adrian Brown, PhD, NIHR Advanced Fellow and Associate Professor in Nutrition and Dietetics at University College London and programme co-lead of the MSc Dietetics (Pre-registration) course

Systematic review identifies patient and clinician barriers to obesity management before kidney transplantation, with Adrian Brown, PhD.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Barriers to Obesity Management in Kidney Failure Before Transplantation

Mauro Cancian, MD, PhD, head of the allergy division at the University of Padua.

Updated HAE guidelines support early self-treatment; Cancian discuss transitioning patients from injectable on-demand therapy to oral sebetralstat after KONFIDENT data.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Transitioning to Oral On-Demand HAE Therapy, With Mauro Cancian, MD, PhD

Rare kidney diseases are hard to detect early, but precision therapies and updated guidelines offer new ways to improve patient outcomes.


RDR Alert®

The Rare Disease Report page is a resource for medical news and expert insights on rare diseases. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for sickle cell disease, multiple myeloma, and more.

Rare Kidney Disease: Advances in Early Detection, Precision Therapies, and Clinical Practice Shifts With Swati Arora, MD

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recent approval and what it means for Wegovy 7.2 mg in the US.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Novo Nordisk Gains European Approval for Semaglutide 7.2 mg, Submits Application to FDA

Susan Taylor, MD, a professor and vice chair for Diversity, Equity, and Inclusion at the Perelman School of Medicine. 

This new February episode of the Skin of Color Savvy podcast highlights why 2026 may be the year of skin health equity in the dermatology field.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Skin of Color Savvy: Why 2026 Is the Year of Skin Equity, With Susan Taylor, MD, Nada Elbuluk, MD, MSc, and Mona Shahriari, MD

Julia W. Angkeow, a PhD candidate and former research technologist at Johns Hopkins Medicine

PhIP-Seq analysis in the Boston Birth Cohort found distinct early-childhood IgG patterns in food allergy, but investigators caution against diagnostic use of IgG testing.

Food Allergy

Early-Life IgG Patterns Linked to Childhood Food Allergy, With Julia Angkeow

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Lilly’s groundbreaking new Zepbound administration option.

Eli Lilly Launches Zepbound KwikPen Multi-Dose Tirzepatide Pen for Adults With Obesity

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

FDA approves dupilumab for allergic fungal rhinosinusitis, supported by phase 3 LIBERTY-AFRS-AIMS data showing reduced symptoms and corticosteroid or surgery use.

Latest News

The Medical Sisterhood: Physician Mom Burnout & Mental Health Strategies, with Jennifer Hsiao, MD

FDA Approves ET-600 Desmopressin Acetate (Desmoda) for Central Diabetes Insipidus

Living Donor Donation Works When Relationships Matter With Mary Roberts, PhD

New Pulmonary Embolism Guidelines Highlight Progress, Encourage Research, With Mark Creager, MD

New Evidence on Meal Timing and Crohn’s Disease Outcomes, With Andres Hurtado-Lorenzo, PhD